David Sas
Pediatric Nephrology Rochester, MN Doctor of Osteopathy
NPI 1922067776 CMS profile 314428
200 1St St Sw, Rochester, MN 55905
General payments
$27,283
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$808,174
Through program year 2025, David Sas of Rochester, MN is reported in the CMS Open Payments database as having received $27,283 across 19 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $808,174 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Pediatric Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,874 | 3 | |
| 2024 | General | $2,957 | 5 | |
| 2023 | General | $2,604 | 3 | |
| 2022 | General | $4,060 | 1 | |
| 2021 | General | $4,322 | 2 | |
| 2020 | General | $4,050 | 1 | |
| 2019 | General | $3,417 | 4 |
Beside peers
- David Sas
- Pediatric Nephrology median
- Middle half of Pediatric Nephrology
- National median
In program year 2025, general payments to David Sas were reported at $5,874. Among 327 Pediatric Nephrology profiles paid that year, the median was $131 and the middle half received between $47 and $474.
Show as a table
| Year | David Sas | Pediatric Nephrology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,417 | $123 | $48–$353 | $163 |
| 2020 | $4,050 | $146 | $24–$2,251 | $114 |
| 2021 | $4,322 | $138 | $26–$1,371 | $132 |
| 2022 | $4,060 | $93 | $25–$427 | $149 |
| 2023 | $2,604 | $105 | $30–$375 | $160 |
| 2024 | $2,957 | $123 | $40–$481 | $164 |
| 2025 | $5,874 | $131 | $47–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Nephrology in Minnesota
Sheldon Mauer
Pediatric Nephrology · Minneapolis, MN
Michelle Rheault
Pediatric Nephrology · Minneapolis, MN
Christian Hanna
Pediatric Nephrology · Rochester, MN
Clifford Kashtan
Pediatric Nephrology · Minneapolis, MN
Scott McEwen
Pediatric Nephrology · Minneapolis, MN
Jennifer Nhan
Pediatric Nephrology · Maple Grove, MN
Related records
Pediatric Nephrology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Nephrology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.